Altimmune, Inc. (ALT)

Altimmune Details Pemvidutide's Path Toward a Liver-Disease Franchise

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

Altimmune to Participate in Stifel Cardiometabolic Forum

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)

BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law

Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT)

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM

Alpha Liquid Terminal Relaunches as the ALT/X Compute Terminal, Pivoting to GPU Pricing, Power and AI Infrastructure Market Data

Bank of America Corp DE Raises Position in Altimmune, Inc. $ALT

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of “Moderate Buy” from Analysts

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune Q2 Earnings Call Highlights

Altimmune Announces Second Quarter 2026 Financial Results and Business Update